Why Merck’s Keytruda is beating Bristol-Myers Opdivo

- November 1, 2017

Bristol-Myers Squibb Co (NYSE:BMY) cancer drug Opdivo has more revenue than Merck & Co’s (NYSE:MRK) Keytruda, but that’s about it, and it won’t last long. I urge investors and BNL Members to check out this post here on HADE Platform for a better explanation, and to see interactive charts of side by side analysis for Keytruda vs Opdivo.

These are two very important drugs for both companies, with mega-blockbuster potential. You can also see the community feed on HADE Platform for interactive analysis, charts, and tables.

This entry was posted in HADE Platform, Healthcare & Biotech, Members Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!

%d bloggers like this: